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Abstract 
Aims: Vascular calcification is a major cause of morbidity and mortality. Fibroblast growth factor-2 
(FGF-2) plays an instructive role in osteogenesis and bone development, but its role in vascular 
calcification was unknown. Therefore, we investigated the involvement of FGF-2 in vascular 
calcification and determined the mechanism by which it regulates this process.   
Methods and Results: We demonstrate that FGF-2 expression is increased in vascular smooth 
muscle cells (VSMCs) induced to deposit a mineralized matrix by incubation with β-glycerophosphate. 
FGF-2 is also localized to sites of calcification within human atherosclerotic plaques. The expression 
of syndecan-4, a heparan sulfate proteoglycan which regulates FGF-2 signaling, is also increased in 
mineralizing VSMCs and co-localizes with FGF-2 in human calcified atherosclerotic plaques. 
Exogenous FGF-2 inhibits VSMC mineralization, and this inhibition is reduced when syndecan-4 
expression is knocked-down using siRNA. Biochemical inhibition of FGFR signaling using a pan 
FGFR inhibitor (BGJ398) or knocking-down syndecan-4 expression in VSMCs using siRNA increases 
VSMC mineralization. These increases are prevented by inhibiting transforming growth factor-β 
(TGFβ) signaling with SB431542, suggesting cross-talk between FGF-2 and TGFβ signaling is crucial 
for the regulation of VSMC mineralization. Syndecan-4 can also regulate FGF-2 signaling directly via 
protein kinase Cα (PKCα) activation. Biochemical inhibition of PKCα activity using Gö6976, or siRNA-
mediated suppression of PKCα expression increases VSMC mineralization; this increase is also 
prevented with SB431542. Finally, the ability of FGF-2 to inhibit VSMC mineralization is reduced 
when PKCα expression is knocked-down.  
Conclusion: This is the first demonstration that syndecan-4 promotes FGF-2 signaling, and in turn, 
suppresses VSMC mineralization by down-regulating TGFβ signaling. Our discoveries that FGF-2 and 
syndecan-4 expression is increased in mineralizing VSMCs and that PKCα regulates FGF-2 and 
TGFβ signaling in VSMCs suggests that the syndecan-4/FGF-2/TGFβ signaling axis could represent 
a new therapeutic target for vascular calcification. 
Introduction 
Vascular calcification is the formation of mineralized tissue, bone and/or cartilage within the vessel 
wall. Most patients with cardiovascular disease have some calcification, although it is most prevalent 
in patients with chronic kidney disease, type 2 diabetes mellitus and atherosclerosis.1,2 Calcification is 
not only highly prevalent in these diseases, but there is now substantial evidence that it contributes to 
the morbidity and mortality associated with these common conditions.3,4  
Vascular calcification is an active cell-regulated process, involving the osteogenic differentiation of 
vascular smooth muscle cells (VSMCs), VSMC apoptosis, calcifying matrix vesicle/exosome release 
and matrix mineralization.5,6 Existing approaches for the prevention of vascular calcification are 
limited; therefore, there is an urgent need to identify new therapeutic targets to treat this devastating 
pathology.  
The fibroblast growth factors (FGFs) are a large family of secreted glycoproteins that can be classified 
as either paracrine- or endocrine-acting. Paracrine FGFs, such as FGF-2, are readily sequestered to 
the extracellular matrix by heparan sulfate proteoglycans (HSPGs) to limit their diffusion within the 
extracellular space. For signal propagation, the paracrine FGFs bind to a cell surface FGF-receptor 
(FGFR1-5) in a ternary complex consisting of FGF, FGFR and HPSGs leading to the activation of 
downstream signaling events via phospholipase Cγ and protein kinase C (PKC), Ras-Erk1/2 or PI3K-
Akt.7  
FGF-2 is a critical regulator of osteogenesis and bone development8,9, although its role in this process 
is complex. Bone formation and mineralization are reduced in FGF-2-null mice.10,11 However, whilst 
short-term FGF-2 treatment stimulates matrix mineralization in calvarial osteoblasts12,13 and 
mesenchymal stem cells14, continuous FGF-2 treatment inhibits mineralization by these cells.12-16 
These studies suggest that FGF-2 is required to promote bone mineralization, but then must be down-
regulated so mineralization can proceed. 
Previous studies have shown that short-term FGF-2 treatment stimulates the expression of the 
osteogenic markers in rat VSMCs.17 However, the potential role of FGF-2 in VSMC mineralization is 
currently unknown. Therefore, this study investigated whether FGF-2 regulates VSMC mineralization. 
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We demonstrate that FGF signaling plays an inhibitory role in this process by interacting with its co-
receptor, syndecan-4, and down-regulating transforming growth factor-β (TGFβ) signaling in VSMCs.   
Materials and Methods 
Detailed experimental protocols are in the online supplement. 
Reagents 
Reagents were analytical grade and obtained from Sigma-Aldrich (UK) unless otherwise stated. 
Recombinant human FGF-2 (#100-18B) was from Peprotech (UK), recombinant human TGFβ1 
(#240-B) from R&D Systems (UK), BGJ398 from Santa Cruz (USA), Gӧ6976 from Cell Signaling 
(USA) and SB431542 from Sigma-Aldrich (UK). An equivalent volume of vehicle was used a control 
for each compound in experiments: 0.1% (w/v) bovine serum albumin (BSA) in 5 mM TRIS for FGF-2, 
dimethyl sulfoxide (DMSO) for BGJ398, Gӧ6976 and SB431542, and 0.1% (w/v) BSA in 4 mM HCl for 
TGFβ1. Antibodies to phosphorylated Smad2 (#3108), Smad2 (#5339), protein kinase Cα (PKCα, 
#2056), phosphorylated Akt (#4060), Akt (#9272), phosphorylated Erk1/2 (#4377) and Erk1/2 (#4695) 
were from Cell Signaling (USA). Antibodies to syndecan-4 were from Santa Cruz (sc-12766) or 
Biovision, USA (#3644). Antibodies to FGF-2 (sc-79) were from Santa Cruz (USA), phosphorylated 
PKCα (07-790) from Merck Millipore (Germany) and β-actin (#A1978) from Sigma-Aldrich (UK).  
Immunohistochemistry 
Human atherosclerotic coronary arteries were used for the detection of FGF-2 (n=7) and syndecan-4 
(n=5) by immunohistochemistry.18 Calcification was detected using von Kossa staining. Images were 
acquired using a 20x/0.80 Plan Apo objective using the 3D Histech Pannoramic 250 Flash II slide 
scanner. Human tissue was obtained with informed consent and with approval from the Local and 
National Research Ethics Committees (STH 16346, 12/NW/0036). This study conforms to the 
Declaration of Helsinki. 
Cell culture 
Bovine VSMCs were isolated from aortic explants obtained from a local abattoir, and routinely 
cultured in high glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 1.4 μM streptomycin, 1 mM sodium pyruvate, 1x non-essential amino 
acids and 10% (v/v) fetal calf serum (FCS), referred to as 10% FCS-DMEM. For mineralization 
assays, cells were cultured in 10% FCS-DMEM until confluent (day 0), and then in 10% FCS-DMEM 
and 3 or 5 mM β-glycerophosphate (β-GP) for up to 18 days.19 Controls were cultured without β-GP. 
Four preparations of uncloned VSMCs isolated from different animals were used for these studies; 
different batches of cells were used in independent experiments. Unless otherwise stated, in vitro 
studies used bovine VSMCs. Cells were used between passage 10-13. 
Human coronary artery VSMCs were routinely cultured in medium 231 supplemented with smooth 
muscle growth supplement (Gibco, Life Technologies). For mineralization assays, cells were cultured 
in medium 231 supplemented with smooth muscle growth supplement until confluent (day 0), and 
then with 5 mM β-GP and 0.9 mM calcium chloride for up to 40 days. The final concentration of 
calcium chloride in the human VSMC calcifying media was 2.7 mM. Controls were cultured without β-
GP and additional calcium chloride. Two preparations of human VSMCs (passage 6-7) were used for 
these studies; different batches of cells were used in independent experiments.       
Small interfering RNAs (siRNAs) 
VSMCs were transfected with siRNAs against syndecan-4 (S459980, Ambion®, Life Technologies, 
UK) or PKCα (SI01965138, Qiagen, UK) using RNAiMAX (Invitrogen™, Life Technologies, UK). A 
random control siRNA (#1027281; Qiagen, UK) was the control. All siRNAs were used at a final 
concentration of 20 nM. For signaling assays, VSMCs were cultured for up to 7 days, with repeated 
siRNA transfections every 48-72 hours. For mineralization assays, VSMCs were transfected twice 
with siRNA (with 48-72 hours between transfections) prior to β-GP treatment. During β-GP treatment, 
siRNAs were removed after 4 hours and fresh medium containing β-GP was added to the cells 
between transfections.  
Alizarin red staining 
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Mineral deposition was confirmed by staining with 40 mM alizarin red (pH 4.1) and quantified by dye 
elution.19 The absorbance values for VSMC mineralization were: early mineralization (0.09-0.2), mid 
mineralization (0.21-0.6) and late mineralization (≥0.61).   
Immunoblotting 
Cell lysates were analyzed for FGF-2, syndecan-4, phosphorylated Smad2, Smad2, phosphorylated 
PKCα, PKCα, phosphorylated Akt, Akt, phosphorylated Erk1/2 and Erk1/2 by immunoblotting.20 β-
actin was the loading control. Immunoblots were quantified using ImageJ.  
RNA isolation and quantitative polymerase chain reaction (qPCR) 
RNA was isolated using the RNeasy Mini Kit (Qiagen) and cDNA synthesized using Taqman® 
Reverse Transcription Reagents (Invitrogen™, Life Technologies). qPCR was performed using SYBR 
Green PCR master mix (Applied Biosystems, Life Technologies) and the CFX96 or CFX384 Real-
Time PCR system (Bio-Rad, UK). Primer sequences are in the online supplement. All samples were 
amplified in duplicate and averaged to produce one data-point. The expression of each gene was 
normalized to the reference genes (ribosomal protein L12 (RPL12) and peptidylprolyl isomerase A 
(PPIA)) using the comparative Ct method.   
Statistical analysis 
Data are presented as the mean ± standard error of the mean (SEM). Data were normalized where 
required using log10 and statistical comparisons were made using t-tests or one-way ANOVA. Data 
with two or more variables were analyzed with a 2-way ANOVA. Where normality could not be 
confirmed, data were analyzed using a Mann-Whitney t-test. A value of P<0.05 was considered 
statistically significant. 
Results 
FGF-2 inhibits mineral deposition by VSMCs 
FGF-2 plays an instructive role in osteogenesis12-14, but the potential involvement of FGF-2 in vascular 
calcification was unknown. To investigate FGF-2 expression during VSMC mineralization, a well-
established in vitro model of vascular calcification was used.19 VSMCs deposit a mineralized matrix 
when cultured from confluence (day 0) in the presence of β-GP, and the extent of mineralization 
increased with time (Figure 1A). No mineralization was detected in controls cultured without β-GP 
(Figure 1A).  
RNA and protein were isolated from VSMCs at specific time-points: early mineralization (days 9-10), 
mid mineralization (days 10-12) and late mineralization (days 12-18). RNA and protein were also 
isolated from VSMCs cultured without β-GP at these same time-points. FGF-2 mRNA (~40-fold; 
Figure 1B) and protein (~2.5-fold increase; Figure 1C) expression were significantly increased in β-
GP-treated VSMCs at late mineralization when compared to controls at the same time-point. In 
contrast, FGF-2 expression was not increased in VSMC preparations that do not deposit a 
mineralized matrix in the presence of β-GP (Figure 1D) confirming that the changes observed in FGF-
2 are either necessary for, or are a consequence of, VSMC mineralization and are not due to 
extended culture in the presence of β-GP.  
To determine whether FGF-2 regulates VSMC mineralization, VSMCs were cultured with β-GP plus 
vehicle or FGF-2 (25 or 50 ng/ml). Exogenous FGF-2 significantly reduced β-GP-induced 
mineralization when compared to the vehicle and β-GP control (Figure 2A). The addition of FGF-2 at 
different time-points during the mineralization protocol (i.e. 0, 2, 4 or 6 days after addition of β-GP) 
also significantly reduced β-GP-induced mineralization in VSMCs compared to controls (Figure S1), 
suggesting FGF-2 can also suppress matrix mineralization when added to cells which are primed to 
mineralize.   
We next investigated the role of FGF-2-dependent fibroblast growth factor receptor (FGFR) signaling 
during VSMC mineralization using the pan-FGFR inhibitor BGJ398. BGJ398 markedly inhibited FGF-
2-induced Akt and Erk1/2 phosphorylation in VSMCs (Figure 2B); BGJ398 also increased β-GP-
induced VSMC mineralization compared to the vehicle and β-GP control (~4.5-fold increase with 1 μM 
BGJ398; Figure 2C). This result was verified in mineralizing human VSMCs (Figure 2D).  BGJ398 did 
not induce VSMC mineralization in the absence of raised phosphate levels (Figure S2A), nor did it 
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induce mineralization in preparations of VSMCs that do not mineralize in the presence of β-GP 
(Figure S2B), suggesting that inhibition of FGFR signaling does not drive VSMC mineralization on its 
own, but it accelerates mineralization in VSMCs that are already primed to mineralize.  
FGF/TGFβ cross-talk regulates mineral deposition by VSMCs 
The above results demonstrate FGF-2 and FGFR signaling reduce matrix mineralization in VSMCs, 
but how FGF-2 mediates this effect was unknown. Recent studies have shown that inhibiting FGF 
signaling increases TGFβ signaling in VSMCs.21,22 As TGFβ1 accelerates mineral deposition by 
calcifying vascular cells23, we next investigated the relationship between FGF and TGFβ signaling in 
VSMC mineralization.     
To confirm TGFβ signaling regulates VSMC mineralization, VSMCs were cultured with β-GP plus 
vehicle or TGFβ1 (0.1 or 1 ng/ml). Exogenous TGFβ1 significantly increased β-GP-induced VSMC 
mineralization when compared to the vehicle and β-GP control (Figure 3A). In contrast, inhibiting 
endogenous TGFβ signaling using the type 1 TGFβ receptor (TGFβR1) kinase inhibitor, SB431542 
(0.1 or 1 µM), significantly reduced VSMC mineralization when compared to the vehicle and β-GP 
control (Figure 3B).      
TGFβR activation leads to Smad2 phosphorylation.21,22 Previous studies have shown that decreased 
Smad2 phosphorylation co-localizes with increased FGFR1 phosphorylation in the medial layer of 
atherosclerotic human coronary arteries.22 In the late stages of matrix mineralization, Smad2 
phosphorylation was significantly reduced in β-GP-treated VSMCs when compared to controls at the 
same time-point (4-fold; Figure 3C). This decrease in Smad2 phosphorylation coincided with 
increased FGF-2 expression in β-GP-treated VSMCs (compare Figures 1B, 1C and 3C).  
To confirm FGF regulates TGFβ signaling in VSMCs, FGFR signaling was inhibited using BGJ398 
and cells were incubated with TGFβ1 for up to 60 minutes. TGFβ1-induced Smad2 phosphorylation 
was significantly increased in VSMCs treated with BGJ398 after 30 and 60 minutes (Figure 3D); this 
increase was prevented by co-incubation with SB431542 (Figure 3D). The relationship between FGF 
and TGFβ signaling in matrix mineralization was also studied by incubating VSMCs with both 
inhibitors. As before, BGJ398 significantly increased β-GP-induced VSMC mineralization compared to 
the vehicle and β-GP control (Figure 3E); this increase was prevented by co-incubation with 
SB431542 (Figure 3E). Together these results suggest FGFR inhibition increases matrix 
mineralization by up-regulating TGFβ signaling in VSMCs.  
Syndecan-4 expression co-localizes with FGF-2 in calcified vessels  
Syndecan-4 is a transmembrane HSPG that functions as an adhesion receptor and growth factor co-
receptor, eliciting signals in response to the extracellular microenvironment.24,25 Atherosclerotic 
plaque susceptibility is increased in syndecan-4/low-density lipoprotein receptor double knock-out 
mice fed a high-fat diet26; but its role in vascular calcification was unknown. As syndecan-4 is a critical 
regulator of FGF-2 signaling27,28, we next investigated the potential involvement of syndecan-4 in 
VSMC mineralization, and examined whether syndecan-4 regulates FGF-2/TGFβ signaling in this 
process. 
Syndecan-4 mRNA expression was markedly increased in β-GP-treated VSMCs, with a ~5-fold 
increase at late mineralization compared to the same time-point controls (Figure 4A). This increase in 
syndecan-4 mRNA expression coincided with increased FGF-2 expression and decreased Smad2 
phosphorylation in β-GP-treated VSMCs (compare Figures 1B, 1C, 3C and 4A). In contrast, 
syndecan-1 expression was significantly decreased in β-GP-treated VSMCs compared to controls, 
with a ~2-fold decrease at late mineralization (Figure 4A). No significant changes were detected in 
syndecan-2 or syndecan-3 mRNA (Figure 4A). Furthermore, syndecan-1 and syndecan-4 mRNA 
expression did not change when VSMC preparations which do not deposit a mineralized matrix in the 
presence of β-GP were analyzed (Figure 4B).   
Syndecan-4 and FGF-2 expression in human atherosclerotic arteries was also examined. FGF-2 and 
syndecan-4 staining was localized to areas directly adjacent to, and within, calcified regions of 
atherosclerotic arteries (representative images of three atherosclerotic lesions from two different 
donors are shown in Figure 4Ci-iii). No staining was observed in the rabbit IgG controls (Figure 4Ci-
iii).  
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FGF-2 inhibits mineral deposition via syndecan-4 
To determine the role of syndecan-4 in VSMC mineralization, siRNA was used to knock-down 
syndecan-4 expression (Figure 5A). Syndecan-4 knock-down significantly increased β-GP-induced 
VSMC mineralization compared to control siRNA-treated cells cultured with β-GP (Figure 5B). 
Knocking-down syndecan-4 expression in VSMCs cultured in control media did not induce matrix 
mineralization on its own (Figure S3A). Furthermore, knocking-down syndecan-4 expression in a 
preparation of VSMCs that do not mineralize in the presence of β-GP did not induce matrix 
mineralization (Figure S3B).    
Syndecan-4 knock-down or biochemical inhibition of FGF-2-dependent FGFR signaling increases 
VSMC mineralization, suggesting syndecan-4 and FGF-2 expression are increased in mineralizing 
VSMCs to prevent further calcification. To investigate the link between FGF-2 and syndecan-4 in 
regulating VSMC mineralization, control siRNA- and syndecan-4 siRNA-transfected VSMCs were 
cultured with vehicle or FGF-2 in the presence of β-GP. As before, FGF-2 inhibited mineralization 
whereas syndecan-4 knock-down markedly increased mineralization (Figure 5C). Furthermore, the 
inhibitory effect of FGF-2 on matrix mineralization was partially prevented by knocking-down 
syndecan-4 expression (Figure 5C). However, FGF-2 was still able to inhibit mineralization in 
syndecan-4 knock-down VSMCs (Figure 5C), suggesting FGF-2 can also signal independently of its 
co-receptor, syndecan-4.  
Inhibiting FGFR signaling increases TGFβ signaling in VSMC (Figure 3D) and inhibiting TGFβ 
signaling prevents FGFR inhibition from increasing VSMC mineralization (Figure 3E). Therefore, to 
determine if TGFβ signaling is also responsible for the increased matrix mineralization in syndecan-4 
knock-down VSMCs, syndecan-4 siRNA-transfected VSMCs were cultured with β-GP and vehicle or 
SB431542 (1 μM). Control siRNA-transfected VSMCs cultured with β-GP were used as controls. 
Knocking-down syndecan-4 expression in VSMCs significantly increased β-GP-induced matrix 
mineralization; this increase was prevented by co-incubation with SB431542 (Figure 5D). These 
results suggest syndecan-4 and FGF-2 both suppress matrix mineralization by down-regulating TGFβ 
signaling in VSMCs.   
PKCα signaling regulates mineral deposition 
The cytoplasmic domain of syndecan-4 interacts with, and activates, PKCα29,30 and the syndecan-
4/PKCα complex regulates FGF-2-induced Akt phosphorylation in endothelial cells.27,28 To investigate 
the link between FGF-2, syndecan-4 and PKCα in VSMCs, syndecan-4 and PKCα were knocked-
down using siRNA and the cells were incubated with vehicle or FGF-2 for 5 minutes and down-stream 
signaling via Akt assessed. FGF-2-induced Akt phosphorylation was reduced in syndecan-4 siRNA-
transfected VSMCs (Figure 6A) and PKCα siRNA-transfected VSMCs (Figure 6B&C). Western 
blotting revealed a trend towards decreased phosphorylated PKCα during the late stages of VSMC 
mineralization (Figure 7A). Therefore, we next investigated whether PKCα regulates FGF/TGFβ 
signaling and mineralization in VSMCs.  
Knocking-down PKCα with siRNA (Figure 7B) or inhibiting PKCα activity with Gö6976 (1 μM) (Figure 
7C) significantly increased β-GP-induced VSMC mineralization compared to the relevant controls.  
Gö6976 also increased mineralization in human VSMCs (Figure 7D). Knocking-down PKCα 
expression in VSMCs cultured in control media (Figure S3A), or culturing VSMCs in control media 
with Gö6976  (Figure S3C) did not induce matrix mineralization. Also Gö6976 did not induce 
mineralization in a preparation of VSMCs that do not mineralize in the presence of β-GP (Figure 
S3D). These results suggest that loss or inhibition of PKCα is not a driver of VSMC mineralization per 
se, but it accelerates mineralization in VSMCs which are already primed to mineralize.  
To further define the link between FGF-2/syndecan-4 and PKCα in regulating VSMC mineralization, 
control siRNA- and PKCα siRNA-transfected VSMC were cultured with vehicle or FGF-2 in the 
presence of β-GP. As before, FGF-2 reduced mineralization whereas PKCα knock-down markedly 
increased mineralization (Figure 7E). PKCα knock-down reduced the inhibitory effect of FGF-2 on 
mineralization (Figure 7E), suggesting the FGF-2/syndecan-4 signaling axis may, at least in part, 
regulate VSMC mineralization via PKCα. FGF-2 was still able to inhibit mineralization in PKCα knock-
down VSMCs (Figure 7E), suggesting that FGF-2 can also signal via other downstream signaling 
pathways.   
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To determine if increased TGFβ signaling mediates the increased mineralization in PKCα knock-down 
VSMCs, PKCα siRNA-transfected VSMCs were cultured with β-GP and vehicle or SB431542 (1 μM). 
Control siRNA-transfected VSMCs cultured with β-GP were controls. SB431542 prevented PKCα 
knock-down from increasing β-GP-induced matrix mineralization in VSMCs (Figure 7F), suggesting 
loss of PKCα increases matrix mineralization by up-regulating TGFβ signaling in VSMCs.    
 
Discussion 
We demonstrate the expression of FGF-2 and its co-receptor, syndecan-4, are increased in 
mineralizing VSMCs and at sites of calcification in human atherosclerotic plaques, and that 
biochemical inhibition of FGFR signaling or knocking-down syndecan-4 expression increases VSMC 
mineralization. Importantly, syndecan-4 is, at least in part, responsible for the inhibition of VSMC 
mineralization by FGF-2, suggesting syndecan-4 expression is increased in mineralizing VSMCs to 
maintain FGF-2 signaling. We also show syndecan-4 and FGF-2 signaling suppress the deposition of 
a mineralized matrix by down-regulating TGFβ signaling. Finally, we demonstrate that PKCα, which is 
activated in a cytoplasmic domain-dependent manner by syndecan-429,30, regulates FGF-2/TGFβ 
signaling and mineralization in VSMCs. Together, these results demonstrate a novel feedback 
mechanism whereby mineralizing VSMCs increase FGF-2 and syndecan-4 expression and down-
regulate TGFβ signaling to prevent more extensive calcification.   
This is the first demonstration that FGF-2 expression is increased in mineralizing VSMCs in vitro, and 
that FGF-2 is localized to calcified regions of human atherosclerotic plaques. Consistent with these 
findings, FGF-2 is expressed adjacent to calcified regions in valve leaflets.31 FGF-2 mRNA expression 
is also increased during the osteogenic differentiation and mineralisation of osteoprogenitors32, and is 
expressed at sites of bone formation in vivo.33 FGF-2 plays a complex role in osteoblast 
mineralization, with its effects dependent on the timing and duration of signaling.12-14 Consistent with 
these studies, we show that continuous FGF-2 treatment inhibits β-GP-induced VSMC mineralization. 
The addition of FGF-2 after the commencement of β-GP treatment also reduces VSMC 
mineralization, supporting the suggestion that increases in FGF-2 expression during late 
mineralization may put a ‘brake’ on this process. Indeed, FGF-2 stimulates the osteogenic potential of 
calvarial osteoblasts and mesenchymal stem cells during the early stages of differentiation, but must 
then be down-regulated for mineralization to proceed.12-14  
It is well established that syndecan-4 is a critical regulator of FGF-2 signaling27,28, but it is currently 
unknown how the transcription of syndecan-4 and FGF-2 is regulated in mineralizing VSMCs. 
Previous studies have reported that FGF-2 synergizes with Runx2 to enhance syndecan-4 mRNA 
expression in calvarial osteoblasts34, but we found that 24-hour FGF-2 treatment has no effect on 
syndecan-4 mRNA expression in VSMCs (Figure S4). It is possible, therefore, that raised levels of 
Runx2 are required for FGF-2 to induce syndecan-4 expression in these cells e.g. as observed during 
VSMC osteogenic differentiation and mineralization.  
A role for TGFβ1 in vascular calcification was first suggested by Watson et al. who reported TGFβ1 
increased mineralized nodule formation in bovine calcifying vascular cells.23 More recent studies have 
shown that inhibition of TGFβR1 using SB431542 inhibits VSMC mineralization.35,36 We also show 
that TGFβ1 accelerates mineral deposition by bovine VSMCs, whereas SB431542 inhibits it. 
Furthermore, we show FGF-2 expression is increased in mineralizing VSMCs and TGFβ signaling is 
concomitantly reduced to minimize further calcification. Previous studies in VSMCs have shown that 
suppressing FGF signaling results in reduced let-7 microRNA, leading to increased TGFβR1 receptor 
expression and TGFβ signaling activation.22 It is therefore possible that FGF-2/TGFβ cross-talk may 
also be mediated via let-7 microRNA in mineralizing VSMCs.  
Several studies have suggested PKCα normally acts to suppress bone formation.37,38 Consistent with 
a previous study in mouse VSMCs39, we show that inhibiting PKCα activity with Gö6976 or knocking-
down PKCα expression increases VSMC mineralization. Moreover, we demonstrate that this increase 
in mineralization is prevented by inhibiting TGFβR1 signaling. The crucial role of PKCα in regulating 
mineralization is further highlighted by our demonstration that knocking-down PKCα reduces the 
ability of FGF-2 to inhibit VSMC mineralization. Over-expressing PKCα in an osteoblastic cell line 
reduces alkaline phosphatase activity and the expression of osteogenic marker genes in these cells37; 
however, the effects of over-expressing PKCα on osteoblast or VSMC mineralization are unknown. As 
PKCα is downstream of FGF-2/syndecan-4, a possible focus for therapeutic targeting in vascular 
calcification may be the modulation of PKCα activation/signaling in VSMCs.  
CVR-2016-439 
 
8 
 
A potential limitation of our study is that the signaling data were obtained following short-term 
incubation of the VSMCs with growth factors and/or inhibitors; whereas the mineralization data were 
obtained following incubation of the cells with these same reagents for up to 14 days. However, 
although caution should be taken when extrapolating between these two sets of data, our study 
clearly demonstrates that signaling and mineralization are both affected by these treatments. 
 
Whilst our results indicate an important role for syndecan-4 in regulating FGF/TGFβ signaling during 
VSMC mineralization, other PGs could also regulate these signaling pathways in this process. Indeed, 
our data show the expression levels of several other PGs are modulated during VSMC mineralization 
(Figure S5). For example, glypican-4 expression is also up-regulated in β-GP-treated VSMCs (Figure 
S5). Glypican-4 binds FGF-240 and may therefore also affect FGF-2/FGFR signaling in VSMCs, 
although glypican-4 wouldn’t directly activate PKCα. Decorin has also been shown to promote 
mineralization by increasing TGFβ signaling in VSMCs.35 Future studies could, therefore, determine 
whether these PGs also regulate FGF and TGFβ cross-talk during VSMC mineralization.  
In conclusion, our study has identified a novel potential therapeutic target pathway in the control of 
vascular disease. We highlight syndecan-4/FGF-2/TGFβ signaling as a critical regulator of VSMC 
mineralization. Intriguingly, both syndecan-4 and FGFR signaling appear to be important in this 
process. It remains to be determined whether syndecan-4 and FGFR regulate mineralization in 
convergent or parallel pathways. It is possible that syndecan-4 may act to prevent excessive 
mineralization via two mechanisms: (a) interacting as a co-receptor for FGF-2 and inducing down-
stream signaling via FGFR and (b) via interaction with PKCα. These pathways may then coalesce to 
suppress mineralization induced by TGFβ. Although this dual activity of syndecan-4 is well 
established in other systems (e.g. during neural induction41) its role here is of particular importance 
given the current need for novel drugs to treat vascular disease.  
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Figure 1. FGF-2 expression is up-regulated during VSMC mineralization. VSMCs (day 0) were 
incubated ± 3 mM β-GP for up to 18 days. (A) VSMCs were stained with alizarin red (bar=500 µm) 
and mineral deposition quantified by dye elution (n=6 independent experiments). FGF-2 expression 
was measured using (B) qPCR (data expressed relative to day 0; n=9 independent experiments) and 
(C) immunoblotting of cell lysates (FGF-2 is expressed relative to β-actin; n=6 independent 
experiments). Molecular weight markers are shown. (D) Two different preparations of non-
mineralizing VSMCs were cultured ± 5 mM β-GP from confluence (day 0) for up to 14 days. RNA was 
collected from cells at day 0, 9, 11 and 14. These time-points were chosen as they correspond to the 
time for mineralizing VSMCs (see 1A) to reach early, mid or late mineralization. FGF-2 mRNA 
expression was measured using qPCR (data expressed relative to day 0; n=6 independent 
experiments). (AD) Data are means ± SEM. (A, B, D) Data were normalized using log10 and analyzed 
using 2-way ANOVA with Sidak post-hoc tests. (C) Data were analyzed using a Mann-Whitney t-test. 
*P<0.05.  
Figure 2. FGF-2/FGFR signaling regulates VSMC mineralization. (A) VSMCs were cultured with 
vehicle ± 3 mM β-GP, or FGF-2 (25 or 50 ng/ml) and 3 mM β-GP, stained with alizarin red (bar=500 
µm) and mineral deposition quantified (Vehicle, n=4 independent experiments; Vehicle and β-GP, 25 
ng/ml FGF-2 and β-GP,50 ng/ml FGF-2 and β-G, n=5 independent experiments). (B) VSMCs were 
serum-starved for 2 hours with vehicle (‘veh’) or BGJ398 (0.01-1 µM), and stimulated with FGF-2 for 5 
minutes. Vehicle-treated VSMCs not stimulated with FGF-2 were controls. Cell lysates were 
immunoblotted for phosphorylated Akt (pAkt), total Akt, phosphorylated Erk1/2 (pErk1/2) and total 
Erk1/2. Two independent experiments were performed with two different concentrations of FGF-2 (25 
and 50 ng/ml) with identical results; a representative immunoblot (50 ng/ml FGF-2) is shown. 
Molecular weight markers are shown. (C) VSMCs were cultured with vehicle ± 3 mM β-GP, or 
BGJ398 (0.1 or 1 μM) and 3 mM β-GP for up to 11 days, stained with alizarin red (bar=500 µm) and 
mineral deposition quantified (n=4 independent experiments). (D) Human VSMCs were cultured with 
vehicle ± 5 mM β-GP and 0.9 mM calcium chloride, or 1 μM BGJ398 ± 5 mM β-GP and 0.9 mM 
calcium chloride, stained with alizarin red (bar=500 µm) and mineral deposition quantified (n=7 
independent experiments). (A, C, D) Data are means ± SEM. Data were normalized using log10 and 
analyzed using a one-way ANOVA with Dunnett post-hoc tests. *P<0.05.   
Figure 3. FGFR/TGFβ cross-talk regulates mineral deposition by VSMCs. (A) VSMCs were 
cultured with vehicle ± 3 mM β-GP, or TGFβ1 (0.1 or 1 ng/ml) and 3 mM β-GP, stained with alizarin 
red (bar=500 µm) and mineral deposition quantified (n=3 independent experiments). (B) VSMCs were 
cultured with vehicle ± 3 mM β-GP, or SB431542 (0.1 or 1 μM) and 3 mM β-GP, stained with alizarin 
red (bar=500 µm) and mineral deposition quantified (n=3 independent experiments). (C) VSMCs were 
incubated ± 3 mM β-GP for up to 18 days. Cell lysates were isolated at late VSMC mineralization and 
immunoblotted for phosphorylated Smad2 (pSmad2), total Smad2 and β-actin on the same 
membrane. Molecular weight markers are shown. The pSmad2/Smad2 ratio is expressed relative to 
β-actin (n=6 independent experiments). (D) VSMCs were serum-starved for 2 hours (‘0’) with vehicle, 
BGJ398 (1 µM), or with BGJ398 (1 µM) and SB431542 (1 µM), stimulated with 0.5 ng/ml TGFβ1 for 
15, 30 or 60 minutes and immunoblotted for phosphorylated Smad2 (pSmad2), total Smad2 and β-
actin on the same membrane. Molecular weight markers are shown. The pSmad2/Smad2 ratio is 
expressed relative to β-actin (vehicle, BGJ398, n=6 independent experiments; BGJ398 with 
SB431542, n=3 independent experiments). (E) VSMCs were cultured with vehicle ± 5 mM β-GP, 5 
mM β-GP and BGJ398 (1 µM), or with 5 mM β-GP, BGJ398 (1 µM) and SB431542 (1 µM), stained 
with alizarin red (bar=500 µm) and mineral deposition quantified (n=4 independent experiments). (A-
E) Data are means ± SEM. (A, B, E) Data were normalized using log10 and analyzed using a one-way 
ANOVA with Dunnett post-hoc tests. (C) Data were analyzed using a Mann-Whitney t-test. (D) Data 
were analyzed using a 2-way ANOVA with Sidak post-hoc tests. *P<0.05.   
Figure 4. Syndecan-4 expression co-localizes with FGF-2 in vascular calcification. (A) VSMCs 
(day 0) were incubated ± 3 mM β-GP for up to 14 days. The mRNA levels of syndecan-1-4 were 
measured using qPCR (as in Figure 1B; n=9 independent experiments for syndecan-1 and syndecan-
4; n=6 independent experiments for syndecan-2 and syndecan-3). (B) Two different preparations of 
non-mineralizing VSMCs were cultured ± 5 mM β-GP from confluence (day 0) for up to 14 days and 
the expression levels of syndecan-1 and syndecan-4 were measured using qPCR (as in Figure 1D; 
n=6 independent experiments). (A, B) Data are means ± SEM. Data were normalized using log10 and 
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analyzed using 2-way ANOVA with Sidak post-hoc tests. *P<0.05. (C) Atherosclerotic coronary artery 
specimens stained with von Kossa’s reagent for calcification (black), anti-FGF-2 antibody, anti-
syndecan-4 antibody, or rabbit IgG. FGF-2 and syndecan-4 (brown) localize to areas adjacent to, or 
within, calcified regions in atherosclerotic plaques (Ci, plaque with extensive calcification, patient 167; 
Cii, plaque with more diffuse calcification, patient 167; Ciii plaque with spicules of calcification, patient 
161). (Ci-iii) Rabbit IgG controls are negative. Bars=200 µm.  
Figure 5. Knocking-down syndecan-4 rescues the inhibitory effect of FGF-2 on VSMC 
mineralization. (A) Syndecan-4 expression was knocked-down in VSMCs using siRNA and 
confirmed using qPCR (upper panel) and immunoblotting (lower panel) (n=4 independent 
experiments).  (B) VSMCs transfected with syndecan-4 siRNA were cultured with 3 mM β-GP for up 
to 9 days. Control siRNA-treated VSMCs cultured ± 3 mM β-GP were controls. Cells were stained 
with alizarin red (bar=500 µm) and mineral deposition quantified (n=8 independent experiments). 
Results were verified using a different siRNA oligonucleotide sequence to target syndecan-4 in 
VSMCs (not shown). (C) Control siRNA and syndecan-4 siRNA-treated VSMCs were cultured with 5 
mM β-GP and vehicle or FGF-2, stained with alizarin red (bar=500 µm) and mineral deposition 
quantified (Control siRNA/β-GP, Control siRNA/β-GP/FGF-2 and Syndecan-4 siRNA/β-GP/FGF-2, 
n=6 independent experiments; Syndecan-4 siRNA/β-GP, n=4 independent experiments). (D) 
Syndecan-4 siRNA-treated VSMCs were cultured with 5 mM β-GP and vehicle or SB431542 (1 µM). 
Control siRNA-treated VSMCs cultured with 5 mM β-GP and vehicle were controls. Cells were stained 
with alizarin red (bar=500 µm) and mineral deposition quantified (n=4 independent experiments). (A-
D) Data are means ± SEM. (A) Data were normalized using log10 and analyzed using a t-test. (B,D) 
Data were normalized using log10 and analyzed using a one-way ANOVA with Dunnett post-hoc tests. 
(C) Data were normalized using log10 and analyzed using a one-way ANOVA with Tukey post-hoc 
tests.  *P<0.05.  
Figure 6. Syndecan-4 and PKCα regulate FGF-2/Akt signaling in VSMCs. (A) Control and 
syndecan-4 siRNA-treated VSMCs were serum-starved for 2 hours (0) and stimulated with vehicle or 
FGF-2 (25 and 50 ng/ml) for 5 minutes. Cell lysates were immunoblotted for phosphorylated Akt 
(pAkt) and total Akt; β-actin was the loading control. (n=6 independent experiments). Molecular weight 
markers and the pAkt/Akt ratio are shown. (B) PKCα expression was knocked-down in VSMCs using 
siRNA and confirmed using qPCR (upper panel) and immunoblotting (lower panel) (n=4 independent 
experiments). (C) FGF-2/Akt signaling assays were performed with control and PKCα siRNA-treated 
VSMCs as described in (A) (n=5 independent experiments). Molecular weight markers and the 
pAkt/Akt ratio are shown. (A-C) Data are means ± SEM. (A, C) Data were analyzed using a 2-way 
ANOVA with Sidak post-hoc tests. (B) Data were normalized using log10 and analyzed using a t-test. 
*P<0.05.  
Figure 7. Inhibiting PKCα activity with Gö6976, or knocking-down PKCα expression using 
siRNA, increases VSMC mineralization. (A) VSMCs (day 0) were incubated ± 3 mM β-GP for up to 
14 days. Cell lysates were isolated at late VSMC mineralization and immunoblotted for PKCα 
phosphorylation (pPKCα), total PKCα and β-actin on the same membrane (n=3 independent 
experiments). Molecular weight markers and the pPKCα/PKCα ratio are shown. (B) VSMCs 
transfected with control siRNA or PKCα siRNA were cultured with 3 mM β-GP for up to 9 days, 
stained with alizarin red (bar=500 µm) and mineral deposition quantified (n=6 independent 
experiments). (C) VSMCs were cultured with 3 mM β-GP and vehicle or 1 μM Gö6976 for up to 11 
days, stained with alizarin red (bar=500 µm) and mineral deposition quantified (n=3 independent 
experiments). (D) Human VSMCs were cultured with vehicle ± 5 mM β-GP and 0.9 mM calcium 
chloride, or 1 μM Gö6976 ± 5 mM β-GP and 0.9 mM calcium chloride, stained with alizarin red 
(bar=500 µm) and mineral deposition quantified (n=7 independent experiments). (E) Control siRNA 
and PKCα siRNA-treated VSMCs were cultured with 5 mM β-GP and vehicle or FGF-2, stained with 
alizarin (bar=500 µm) and mineral deposition quantified (Control siRNA/β-GP, Control siRNA/β-
GP/FGF-2 and PKCα siRNA/β-GP/FGF-2, n=6 independent experiments; PKCα siRNA/β-GP, n=3 
independent experiments).  (F) PKCα siRNA-treated VSMCs were cultured with 5 mM β-GP and 
vehicle or SB431542 (1 µM). Control siRNA-treated VSMCs cultured with 5 mM β-GP and vehicle 
were used as controls. Cells were stained with alizarin red (bar=500 µm) and mineral deposition 
quantified (n=3 independent experiments). (A-F) Data are means ± SEM. (B, C) Data were 
normalized using log10 and analyzed using a t-test. (D, F) Data were normalized using log10 and 
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analyzed using a one-way ANOVA with Dunnett post-hoc tests. (E) Data were normalized using log10 
and analyzed using a one-way ANOVA with Tukey post-hoc tests.  *P<0.05.  
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